Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Innovation Council · Running

StarTric StarTric - A novel transcatheter medical device to treat Tricuspid Regurgitation

Coordinator
Star Tric SRL, Italy
Runs
1 July 2025 to 30 June 2028
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101217016

What the project is doing

In the project's own words, from its summary on CORDIS.

Tricuspid Regurgitation (TR) poses a significant health challenge, affecting millions worldwide. Current treatment options, primarily open-heart surgery, come with inherent risks and are often unsuitable for frail patients. StarTric has pioneered a transcatheter device tailored to the intricate task of addressing TR. Drawing inspiration from the highly successful open-heart ""clover"" technique, this innovative device offers a minimally invasive alternative for TR repair.

The StarTric device will reshape the tricuspid valve into a clover-like configuration, effectively restoring proper valve function. By replicating the efficacy of the clover procedure through transcatheter means, StarTric's solution holds immense promise in transforming the lives of countless patients globally. To bring this breakthrough solution to patients in need, StarTric requires funding support to accelerate development, clinical trials, regulatory approval and commercial efforts.""

Topics

Who is involved

OrganisationCityCountryRole
Star Tric SRLMilanoItalyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI